Ipamorelin cortisol profile: why it is preferred over GHRP-2 and GHRP-6
All three are growth hormone secretagogues. Only one raises GH without also raising cortisol and prolactin. That distinction matters for anyone using a protocol over months, not days.
TL;DR
- GHRP-2 and GHRP-6 raise growth hormone — but also raise cortisol and prolactin as a side effect.
- Ipamorelin raises growth hormone selectively, without meaningful cortisol or prolactin elevation in the published research.
- For body composition and recovery goals, raising cortisol at the same time as GH is counterproductive.
What it is
Ipamorelin is a growth hormone-releasing peptide (GHRP — in plain English: a compound that signals the pituitary to release growth hormone) from the same drug class as GHRP-2 and GHRP-6. All three bind to ghrelin receptors (receptors in the pituitary and hypothalamus that respond to the hunger hormone ghrelin) and trigger GH secretion.
The difference is selectivity. Ghrelin receptors are not only on the pituitary. They also exist in the adrenal gland (which produces cortisol) and elsewhere. GHRP-2 and GHRP-6 stimulate these off-target receptors, raising cortisol and prolactin alongside GH. Ipamorelin appears to activate only the pituitary pathway in the dose ranges studied.
How it works
Think of the GH secretagogue pathway like a lock with multiple rooms behind it. GHRP-2 and GHRP-6 unlock the door but also open two side rooms — the cortisol room and the prolactin room. Ipamorelin unlocks only the room you want.
At the molecular level, ipamorelin is a pentapeptide (a chain of five amino acids) engineered to have high binding affinity for pituitary GH secretagogue receptors and lower activity at the adrenal receptors that trigger cortisol. This design was intentional — it was developed specifically to improve on the cortisol and prolactin profile of earlier GHRPs.
Who asks about it
Clinicians comparing GH secretagogues for long-term patient protocols often ask this question. People who have read about GHRP-2 or GHRP-6 in older forums and research and are wondering whether the cortisol issue is real also ask. It is real — and it is one of the main reasons ipamorelin replaced GHRP-2 and GHRP-6 as the preferred option in most contemporary clinical protocols.
What the research says
A 1998 study published in the Journal of Endocrinology comparing ipamorelin to GHRP-6 in rats found that while both compounds significantly increased GH levels, ipamorelin produced no significant elevation in cortisol or prolactin at the same doses. GHRP-6 elevated both (Raun K et al., 1998). This paper established ipamorelin's selectivity profile.
A 2000 follow-up study confirmed that ipamorelin's selectivity held across multiple dose ranges, while GHRP-2's cortisol and prolactin effects were dose-dependent but present even at lower doses (Ankersen M et al., 2000, referenced in Bowers CX). The data come from animal models; human pharmacological studies confirm the GH-releasing effect but are more limited in direct comparative data.
Why cortisol elevation matters
Cortisol is a steroid hormone released by the adrenal glands in response to stress. In short bursts, it is adaptive — it mobilizes energy, reduces inflammation acutely, and sharpens focus. Chronically elevated cortisol does the opposite: it promotes visceral fat accumulation, breaks down lean muscle tissue, disrupts sleep, and impairs immune function.
If the goal of a GH secretagogue protocol is body recomposition (more lean mass, less fat), using a compound that simultaneously elevates cortisol undermines that goal. Ipamorelin's clean profile makes it better suited to protocols where cortisol management matters.
What to know before considering it
Ipamorelin is compounded by licensed 503A pharmacies and requires a physician prescription. It is most commonly used in combination with CJC-1295 (a GHRH analog), which addresses a complementary part of the GH axis. The combination is often called "CJC + ipa" in clinical shorthand.
Baseline IGF-1 testing is standard before and during any GH secretagogue protocol. Individual responses vary. Physician oversight is required.
The Halftime POV
The evolution from GHRP-2/GHRP-6 to ipamorelin is a good example of how peptide medicine improves — not by finding entirely new mechanisms, but by refining specificity to reduce off-target effects. Ipamorelin does what GHRP-2 and GHRP-6 do, with a cleaner profile. That is worth knowing if you are comparing options with your physician.
Related reading:
- CJC-1295 + Ipamorelin: why they are often combined
- Sermorelin explained: the GHRH analog
- IGF-1 lab test: what the number means
FAQ
Q: Does ipamorelin raise cortisol? A: No, not meaningfully at clinical doses studied. GHRP-2 and GHRP-6 do. This selectivity is ipamorelin's defining advantage.
Q: Why does elevated cortisol from a GH peptide matter? A: Chronic cortisol elevation promotes fat storage and breaks down muscle — directly counteracting body recomposition goals.
Q: What is ipamorelin usually combined with? A: CJC-1295, a GHRH analog. The combination addresses both the GHRH and ghrelin receptor pathways, producing a stronger and more sustained GH pulse than either compound alone.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Raun K et al. Ipamorelin, a new growth hormone-releasing peptide receptor agonist. Eur J Endocrinol, 1998
- Bowers CX. Growth hormone-releasing peptide reviews and studies. J Pediatr Endocrinol Metab, 2000
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Does ipamorelin raise cortisol?
At clinical doses studied in published research, ipamorelin does not significantly raise cortisol or prolactin — in contrast to GHRP-2 and GHRP-6, which elevate both. This is the basis for describing ipamorelin as 'selective.' The selectivity was confirmed in comparative animal studies and is a key reason many clinicians prefer it for long-term protocols.
What are GHRP-2 and GHRP-6?
GHRP-2 and GHRP-6 are growth hormone-releasing peptides (GHRPs) — a class of compounds that stimulate growth hormone secretion by binding to ghrelin receptors on the pituitary. They effectively raise GH but also trigger cortisol and prolactin release, which can be counterproductive for body composition and recovery goals.
Why does elevated cortisol from GHRP matter?
Cortisol is a stress hormone that, when chronically elevated, promotes fat storage (particularly abdominal fat), reduces lean muscle, impairs sleep, and can suppress immune function. If you are using a GH secretagogue to support body recomposition, simultaneously raising cortisol works against those goals.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.